Article Text

other Versions

PDF
An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis
  1. S H Wong1,
  2. M D Saunders1,
  3. A J Larner1,
  4. K Das2,
  5. I K Hart1,*
  1. 1Department of Neurology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK
  2. 2Department of Neuroradiology, The Walton Centre for Neurology and Neurosurgery, Liverpool, UK
  1. Correspondence to Dr Sui Wong, Neurology Specialist Registrar, The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK; suiwong{at}doctors.org.uk

Abstract

Background Voltage-gated potassium channel antibody-positive limbic encephalitis (VGKC+LE) frequently improves with immunotherapy, although the optimum regimen is unknown. The effectiveness of a combination immunomodulatory regimen was tested in consecutive VGKC+LE patients.

Methods This was an open-label prospective study of nine VGKC+LE patients. All patients had plasma exchange (50 ml/kg), intravenous immunoglobulin (2 g/kg) and intravenous methylprednisolone (1 g×3), followed by maintenance oral prednisolone (1 mg/kg/day). Mycophenolate (2 g/day) was used in the first three patients. Assessments included serial clinical, cognitive, brain MRI and VGKC antibody testing.

Results Within 1 week, seizures and hyponatraemia remitted in all affected patients. Cognitive function improved in all patients within 3 months. MRI appearances improved substantially within 9 months, with remission of inflammation in the majority of patients. All achieved immunological remission with normal VGKC antibody titres within 1–4 months. Major adverse events of therapy included one septicaemia and one thrombosis on plasma exchange and one death from sepsis after incidental bowel surgery. One patient remains in remission after 40 months of follow up, 26 months after being off all treatment.

Conclusions Our immunotherapy regimen was effective for the treatment of the clinical, cognitive and immunological features of VGKC+LE. Radiological improvement was seen in the majority. Pending randomised controlled trials, this regimen is proposed for the treatment of VGKC+LE.

  • Voltage-gated potassium channel antibody
  • limbic encephalitis
  • immunotherapy

Statistics from Altmetric.com

Footnotes

  • * Dr Ian Hart died on 10 November 2008

  • Competing interests None.

  • Patient consent Obtained.

  • provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.